MSME (Udyam registered) Ministry of MSME
- Udyam number
- UDYAM-MH-19-0066666
Market Cap
₹92.75 Cr
VAISHALI · NSE
Share Price
₹6.85
-0.29% today
Revenue
₹109 Cr
FY 2025-26 · +9.8% YoY
EBITDA
₹4.11 Cr
Margin 3.8%
Net Profit
₹4.03 Cr
FY 2025-26 · +391.5% YoY
P/E (TTM)
20.8x
P/B 1.2x
Authorised capital
₹27 Cr
Registered with MCA
Paid-up capital
₹27 Cr
Issued & subscribed
About Vaishali Pharma Limited
Data last updated:
Vaishali Pharma Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 25 April 2008 and has been in existence for over 18 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L52310MH2008PLC181632. Its GSTIN is 27AACCV7258G1Z1 (Maharashtra). The company holds 4 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on NSE: VAISHALI.
The company has an authorised share capital of ₹27 Cr and a paid-up capital of ₹27 Cr. It was formerly known as Vaishali Pharma Private Limited. It is led by directors including Atul Arvind Vasani (Managing Director) and Jagruti Atul Vasani (Whole-Time Director).
Its last annual general meeting (AGM) was held on 22 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Mumbai, Maharashtra.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹108.77 Cr, a growth of 9.8% compared to the previous year. For the same year it recorded a net profit of ₹4.03 Cr (net margin 3.7%) and EBITDA of ₹4.11 Cr (EBITDA margin 3.8%). The net worth stands at ₹68.98 Cr (up 6.3% YoY). Total assets are valued at ₹88.16 Cr (up 13.8% YoY).
The company has about 15 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Vaishali Pharma. As per MCA filings, the company has open charges of ₹20.15 Cr and satisfied charges of ₹17.13 Cr on record. Court records list 19 cases involving the company, including 5 filed by the company and 14 filed against it; 6 cases are pending. The company has 135 deals on record (134 market trades, 1 ipo); the latest was in October 2025. The company has 18 MSME Form 1 returns on record between 2019 and 2024, listing 68 overdue payments to 25 micro and small suppliers.
Vaishali Pharma Limited is registered as an MSME under the Udyam registration framework (Reg. No. UDYAM-MH-19-0066666). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website vaishalipharma.com.
Company details
CIN L52310MH2008PLC181632
Registration Number 181632
Incorporation Date 25 April 2008
ROC Mumbai
Listing Status Listed - Listed on NSE (VAISHALI)
Company Status Active
Date of Last AGM 22 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification MSME
Udyam Registration UDYAM-MH-19-0066666
CIN history
Vaishali Pharma has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L52310MH2008PLC181632, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L52310MH2008PLC181632 | Current |
| U52310MH2008PTC181632 | Previous |
| U52310MH2008PLC181632 | Previous |
Key People
Atul Arvind Vasani Managing Director Jagruti Atul Vasani Whole-Time Director Dewansh Ajay Vasani Director Recognitions & Rankings of Vaishali Pharma
Contact details
Vaishali Pharma Limited's registered office is in Mumbai, Maharashtra. Its website is vaishalipharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address706 To 709 7th Fl Aravali Busines Center R. C. Patel Road Off Sodawala Lane Bor, Ivali West, Mumbai, Maharashtra, India – 400092
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Vaishali Pharma Limited, buy the company report.
Comprehensive company report
Vaishali Pharma Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Vaishali Pharma operates one associated brand: Vaishali Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Finished formulations, APIs, and intermediates are manufactured. | vaishalipharma.com |
Business activity
The main business activity of Vaishali Pharma is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Vaishali Pharma Limited, buy the company report.
Financials of Vaishali Pharma Limited
FY 2025-26 filings availableVaishali Pharma Limited reported revenue of ₹108.77 Cr (up 9.8% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue
₹109 Cr
+9.8% YoY
EBITDA
₹4.11 Cr
+608.6% YoY
Profit After Tax
₹4.03 Cr
+391.5% YoY
Net Worth
₹68.98 Cr
+6.3% YoY
Total Assets
₹88.16 Cr
+13.8% YoY
Total Debt
₹18.89 Cr
+53.3% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 109 | 99.03 | 86.28 | 69.66 | 75.82 | 53.77 | 60.09 |
| Revenue growth | +9.8% | +14.8% | +23.9% | -8.1% | +41.0% | -10.5% | - |
| EBITDA | 4.11 | 0.58 | 1.67 | 9.38 | 6.88 | 2.65 | 0.90 |
| EBITDA margin | +3.8% | +0.6% | +1.9% | +13.5% | +9.1% | +4.9% | +1.5% |
| Profit before tax | 5.39 | 1.23 | 0.92 | 8.85 | 5.72 | 1.40 | 0.07 |
| Net profit | 4.03 | 0.82 | 0.71 | 6.61 | 4.02 | 1.04 | 0.02 |
| Net profit margin | +3.7% | +0.8% | +0.8% | +9.5% | +5.3% | +1.9% | +0.0% |
| EPS (₹) | 0.31 | 0.06 | 0.67 | 6.26 | 3.82 | 0.99 | 0.03 |
| Balance sheet | |||||||
| Total assets | 88.16 | 77.49 | 56.53 | 55.46 | 47.35 | 40.45 | 38.56 |
| Net worth | 68.98 | 64.91 | 42.85 | 40.54 | 26.36 | 22.42 | 21.39 |
| Total debt | 18.89 | 12.32 | 13.49 | 14.73 | 20.81 | 17.85 | 17.04 |
| Cash & bank | 1.43 | 1.84 | 1.58 | 0.98 | 1.36 | 0.47 | 0.38 |
| Net working capital | 77.86 | 72.14 | 51.10 | 49.23 | 42.17 | 35.63 | 33.58 |
| Cash flow | |||||||
| Cash from operations | 0.31 | (18.04) | 0.81 | 1.08 | 1.32 | 2.01 | 3.22 |
| Cash from investing | (5.33) | (0.20) | 1.20 | 0.28 | (0.85) | (0.11) | (0.02) |
| Cash from financing | 4.61 | 18.50 | (1.42) | (1.73) | 0.42 | (1.81) | (3.14) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 22.89 | 26.93 | 24.65 | 33.45 | 23.75 | 32.25 | 27.91 | 20.79 |
| Revenue growth (YoY) | -3.6% | -16.5% | -11.7% | +60.9% | +31.4% | - | - | - |
| Other income | 0.58 | 1.26 | 0.89 | 0.84 | 0.84 | 1.00 | 1.07 | 0.71 |
| Total expenses | 21.41 | 27.13 | 23.09 | 32.06 | 22.38 | 38.29 | 26.55 | 18.37 |
| EBITDA | 1.48 | (0.20) | 1.56 | 1.39 | 1.37 | (6.04) | 1.36 | 2.42 |
| EBITDA margin | +6.5% | -0.7% | +6.3% | +4.2% | +5.8% | -18.7% | +4.9% | +11.6% |
| Depreciation | 0.14 | 0.16 | 0.13 | 0.17 | 0.14 | 0.12 | 0.12 | 0.12 |
| Interest | 0.20 | 0.72 | 0.51 | 0.40 | 0.33 | 0.44 | 0.38 | 0.38 |
| Profit before tax | 1.72 | 0.18 | 1.81 | 1.66 | 1.74 | (5.60) | 1.93 | 2.63 |
| Tax | 0.24 | (0.09) | 0.51 | 0.47 | 0.46 | (1.31) | 0.48 | 0.66 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 26 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 22.89 | 26.93 | 24.65 | 33.45 | 23.75 | 32.25 | 27.91 | 20.79 |
| Revenue growth (YoY) | -3.6% | -16.5% | -11.7% | +60.9% | +31.4% | - | - | - |
| Other income | 0.58 | 1.26 | 0.89 | 0.84 | 0.84 | 1.00 | 1.07 | 0.71 |
| Total expenses | 21.41 | 27.13 | 23.09 | 32.06 | 22.38 | 38.29 | 26.55 | 18.37 |
| EBITDA | 1.48 | (0.20) | 1.56 | 1.39 | 1.37 | (6.04) | 1.36 | 2.42 |
| EBITDA margin | +6.5% | -0.7% | +6.3% | +4.2% | +5.8% | -18.7% | +4.9% | +11.6% |
| Depreciation | 0.14 | 0.16 | 0.13 | 0.17 | 0.14 | 0.12 | 0.12 | 0.12 |
| Interest | 0.20 | 0.72 | 0.51 | 0.40 | 0.33 | 0.44 | 0.38 | 0.38 |
| Profit before tax | 1.72 | 0.18 | 1.81 | 1.66 | 1.74 | (5.60) | 1.93 | 2.63 |
| Tax | 0.24 | (0.09) | 0.51 | 0.47 | 0.46 | (1.31) | 0.48 | 0.66 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 109 | 99.03 | 86.28 | 69.66 | 75.82 | 53.77 | 60.09 |
| Revenue growth | +9.8% | +14.8% | +23.9% | -8.1% | +41.0% | -10.5% | - |
| Other income | 3.84 | 3.21 | 2.03 | 2.23 | 1.79 | 1.81 | 2.17 |
| Total expenses | 105 | 98.45 | 84.61 | 60.28 | 68.94 | 51.12 | 59.19 |
| Employee cost | 0.00 | 1.58 | 1.40 | 1.30 | 1.36 | 1.19 | 1.27 |
| EBITDA | 4.11 | 0.58 | 1.67 | 9.38 | 6.88 | 2.65 | 0.90 |
| EBITDA margin | +3.8% | +0.6% | +1.9% | +13.5% | +9.1% | +4.9% | +1.5% |
| Depreciation | 0.60 | 0.49 | 0.51 | 0.50 | 0.46 | 0.43 | 0.44 |
| Interest | 1.96 | 2.07 | 2.27 | 2.26 | 2.49 | 2.63 | 2.56 |
| Profit before tax | 5.39 | 1.23 | 0.92 | 8.85 | 5.72 | 1.40 | 0.07 |
| Tax | 1.36 | 0.41 | 0.21 | 2.24 | 1.70 | 0.36 | 0.05 |
| Net profit | 4.03 | 0.82 | 0.71 | 6.61 | 4.02 | 1.04 | 0.02 |
| Net profit margin | +3.7% | +0.8% | +0.8% | +9.5% | +5.3% | +1.9% | +0.0% |
| EPS (₹) | 0.31 | 0.06 | 0.67 | 6.26 | 3.82 | 0.99 | 0.03 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 26.09 | 26.09 | 10.72 | 10.55 | 10.55 | 10.55 | 10.55 |
| Reserves & surplus | 42.89 | 38.82 | 25.10 | 29.99 | 15.81 | 11.87 | 10.84 |
| Shareholders' funds (net worth) | 68.98 | 64.91 | 42.85 | 40.54 | 26.36 | 22.42 | 21.39 |
| Secured loans | 18.50 | 11.64 | 12.07 | 13.00 | 15.03 | 17.30 | 16.28 |
| Unsecured loans | 0.39 | 0.68 | 1.42 | 1.73 | 5.78 | 0.55 | 0.76 |
| Total debt | 18.89 | 12.32 | 13.49 | 14.73 | 20.81 | 17.85 | 17.04 |
| Total liabilities | 88.16 | 77.49 | 56.53 | 55.46 | 47.35 | 40.45 | 38.56 |
| Assets | |||||||
| Gross block | 5.16 | 4.71 | 3.89 | 3.85 | 3.30 | 2.89 | 2.73 |
| Net block | 1.69 | 1.84 | 1.52 | 1.99 | 1.18 | 1.22 | 1.49 |
| Capital work in progress | 0.25 | 0.25 | 0.74 | 0.67 | 0.49 | 0.05 | 0.08 |
| Investments | 5.43 | 0.43 | 0.43 | 0.43 | 0.43 | 0.43 | 0.43 |
| Inventories | 3.40 | 4.81 | 0.38 | 3.05 | 0.63 | 0.59 | 0.88 |
| Sundry debtors | 50.77 | 46.72 | 49.43 | 53.61 | 58.51 | 66.73 | 47.03 |
| Cash & bank balances | 1.43 | 1.84 | 1.58 | 0.98 | 1.36 | 0.47 | 0.38 |
| Loans & advances | 57.36 | 51.12 | 23.14 | 15.03 | 15.94 | 13.51 | 12.93 |
| Total current assets | 113 | 104 | 74.53 | 72.67 | 76.44 | 81.30 | 61.22 |
| Total current liabilities | 35.10 | 32.35 | 23.43 | 23.44 | 34.27 | 45.67 | 27.64 |
| Net working capital | 77.86 | 72.14 | 51.10 | 49.23 | 42.17 | 35.63 | 33.58 |
| Total assets | 88.16 | 77.49 | 56.53 | 55.46 | 47.35 | 40.45 | 38.56 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 1.84 | 1.58 | 0.98 | 1.36 | 0.47 | 0.38 | 0.32 |
| Net cash from operating activities | 0.31 | (18.04) | 0.81 | 1.08 | 1.32 | 2.01 | 3.22 |
| Net cash from investing activities | (5.33) | (0.20) | 1.20 | 0.28 | (0.85) | (0.11) | (0.02) |
| Net cash from financing activities | 4.61 | 18.50 | (1.42) | (1.73) | 0.42 | (1.81) | (3.14) |
| Net change in cash | (0.41) | 0.26 | 0.59 | (0.37) | 0.89 | 0.09 | 0.06 |
| Closing cash | 1.43 | 1.84 | 1.58 | 0.98 | 1.36 | 0.47 | 0.38 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +9.8% | +14.8% | +23.9% | -8.1% | +41.0% | -10.5% | - |
| EBITDA growth | +608.6% | -65.3% | -82.2% | +36.3% | +159.6% | +194.4% | - |
| PBT growth | +338.2% | +33.7% | -89.6% | +54.7% | +308.6% | +1900.0% | -93.8% |
| Net income growth | +391.5% | +15.5% | -89.3% | +64.4% | +286.5% | +5100.0% | - |
| Revenue CAGR (3Y) | +16.0% | +9.3% | +17.1% | +5.1% | +0.3% | -7.4% | -2.1% |
| EBITDA CAGR (3Y) | -24.1% | -56.2% | -14.3% | +118.4% | +49.2% | -1.6% | -36.2% |
| Profitability & leverage | |||||||
| Net income margin | +3.7% | +0.8% | +0.8% | +9.5% | +5.3% | +1.9% | +0.0% |
| Return on capital employed | - | +4.9% | +5.7% | +21.6% | +18.7% | +10.2% | +6.8% |
| Return on net worth | - | +1.5% | +1.7% | +19.7% | +16.5% | +4.8% | +0.1% |
| Debt / equity | - | 0.24 | 0.34 | 0.53 | 0.79 | 0.80 | 0.80 |
| Long-term debt / equity | - | 0.09 | 0.14 | 0.16 | 0.21 | 0.25 | 0.25 |
| Interest cover | 55.84 | 2,300.00 | 195.69 | 25.45 | 38.79 | 118.47 | 556.52 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 23.08 | 22.29 | 19.49 | 24.50 | 19.14 | 24.68 |
| Inventory turnover | - | 38.16 | 50.31 | 37.86 | 124.30 | 73.16 | 64.61 |
| Debtors turnover | - | 2.06 | 1.67 | 1.24 | 1.21 | 0.95 | 1.25 |
| EPS (₹) | 0.31 | 0.06 | 0.67 | 6.26 | 3.82 | 0.99 | 0.03 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 4.98 | 33.41 | 38.43 | 24.99 | 21.26 | 20.27 |
To see the full year-wise statements and ratios of Vaishali Pharma Limited, buy the company report.
Board of directors of Vaishali Pharma Limited
Vaishali Pharma has 5 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Atul Arvind Vasani | Managing Director | 25 Apr 2008 | 18 Years 6 Months | Current |
| Jagruti Atul Vasani | Whole-Time Director | 12 Nov 2009 | 16 Years 11 Months | Current |
| Dewansh Ajay Vasani | Director | 26 Apr 2018 | 8 Years 6 Months | Current |
| Manish Bhagwandas Ved | Director | 31 Dec 2019 | 6 Years 9 Months | Current |
| Pratik Vikram Jakhelia | Director | 10 Jul 2021 | 5 Years 3 Months | Current |
Auditor
Vaishali Pharma Limited is audited by Raman S. Shah & Associates for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Raman S. Shah & Associates | FY 2023 | 119891W |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 31.60%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 68.40%.
Sep 2026
QUARTER
31.60% Promoters
68.40% Retail & Others
Promoter holding - history
Now 31.60% · Sep 2026High 31.60% · Mar 2026Low 26.30% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 31.60% | 31.60% | 31.60% | 26.30% |
| Public | 68.40% | 68.40% | 68.40% | 73.70% |
Charges & borrowings
Open charges
₹20.15 Cr
Satisfied charges
₹17.13 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 16 May 2025 | 101105558 | Others | ₹9.99 Lakh | Open | |
| 29 Mar 2025 | 101094862 | Yes Bank Limited | ₹5.05 Cr | Open | |
| 05 Jan 2019 | 100237607 | Others | ₹3 Cr | Open | |
| 10 Oct 2013 | 10460225 | Others | ₹12 Cr | Open | |
| 30 Sep 2020 | 100384707 | Others | ₹26 Lakh | Satisfied |
To see the full charge records of Vaishali Pharma Limited, buy the company report.
Total charge records: 13 View all charges
Deals & funding
Vaishali Pharma Limited has 135 deals on record (134 market trades, 1 ipo); the latest was in October 2025.
Total deals
135
Market trades
134
IPO
1
Deals on record (5 of 135)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2025 | Market trade | ₹1.25 Cr | Buyer: an individual Seller: Sawaca Enterprises Limited |
| Oct 2024 | Market trade | ₹3.72 Cr | Buyer: Multiplier Share and Stock Advisors Private Limited , 2 individuals Seller: Multiplier Share and Stock Advisors Private Limited , 2 individuals |
| Oct 2024 | Market trade | ₹1.22 Cr | Buyer: NK Securities Research Private Limited Seller: NK Securities Research Private Limited |
| Oct 2024 | Market trade | ₹1.64 Cr | Seller: F3 Advisors Private Limited |
| Sep 2024 | Market trade | ₹5.04 Cr | Buyer: Hrti Private Limited , NK Securities Research Private Limited , Aakraya Research LLP Seller: Hrti Private Limited , NK Securities Research Private Limited , Aakraya Research LLP |
To see the full deal history of Vaishali Pharma Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Vaishali Pharma Limited has 19 court cases on record: 5 filed by Vaishali Pharma, 14 filed against it. 6 cases are pending and 13 are disposed.
Total cases
19
Filed by the company
5
Filed against the company
14
Pending
6
Disposed
13
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 15 | 10 | 6 |
| NCLT | 4 | 4 | 0 |
Cases on record (5 of 19)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, North West, Delhi | Court case (CS (COMM.)) | Filed against the company by Sterile India Pvt Ltd | Disposed |
| NCLT, Mumbai | Insolvency matter | Filed against the company by Aarti Drugs Limited | Disposed |
| NCLT, Mumbai | Insolvency matter | Filed against the company by Dinesh Remedies Limited | Disposed |
| District court, Vadodara, Gujarat | Criminal complaint | Filed against the company by Century Pharmaceuticals Limited - Balkrishna Shetty | Disposed |
| District court, Mumbai City Civil Court, Maharashtra | Court case (Summons For Judgement) | Filed by the company against Endolabs Healthcare Pvt.Ltd. | Disposed |
To see the full case history of Vaishali Pharma Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Vaishali Pharma Limited was last rated by Crisil on 15 Jan 2019.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 15 Jan 2019 |
To see the full credit ratings and regulatory alerts of Vaishali Pharma Limited, buy the company report.
MSME payment delays
Vaishali Pharma Limited has 18 MSME Form 1 returns on record between 2019 and 2024, listing 68 overdue payments to 25 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 25)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Rajdeep Pharmaceuticals | |||
| Industrial Associates | |||
| an individual supplier | |||
| Bio-Med Health Care Products Private Limited | |||
| an individual supplier |
To see the full MSME payment records of Vaishali Pharma Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Vaishali Pharma Limited has a workforce of 15 employees on its EPFO records as of Apr 04, 2024, across 1 active EPFO establishment.
Employee count
15
Active EPFO establishments
1
Employee growth
-11.76%
GST
Vaishali Pharma has 4 GST registrations: 1 active and 3 cancelled or inactive.
Total GSTINs
4
Active
1
Cancelled / inactive
3
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AACCV7258G1Z1 | Maharashtra | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Vaishali Pharma Limited, buy the company report.
Recent activity
Vaishali Pharma Limited has 19 board changes on record since 2008: 12 appointments and 7 cessations. The latest: Ratnesh Raghunath Singh ceased to be CFO on 28 Feb 2025.
Charges
A charge with Yes Bank Limited of Rs. 5.05 Cr registered on 29 Mar 2025 with Charge ID 101094862 was modified on 30 Aug 2026.
Charges
A charge registered on 30 Sep 2020 via Charge ID 100384707 with Others was fully satisfied on 03 Jul 2026.
Charges
A charge registered on 31 Jan 2015 via Charge ID 10585905 with L&T Housing Finance Limited was fully satisfied on 03 Jul 2026.
Filing
Vaishali Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
Charges
A charge with Others of Rs. 12.00 Cr registered on 10 Oct 2013 with Charge ID 10460225 was modified on 30 Mar 2026.
AGM
Vaishali Pharma Limited last Annual general meeting of members was held on 22 Sep 2025 as per latest MCA records.
Charges
A charge with Others amounted to Rs. 0.10 Cr with Charge ID 101105558 was registered on 16 May 2025.
Charges
A charge with Yes Bank Limited amounted to Rs. 5.05 Cr with Charge ID 101094862 was registered on 29 Mar 2025.
Ceased
Ratnesh Raghunath Singh ceased to be CFO.
Ceased
Ashvin Jamnadas Ganatra ceased to be Director.
Charges
A charge registered on 09 Mar 2017 via Charge ID 100084949 with Others was fully satisfied on 27 Jul 2022.
Ceased
Prataprai Panachand Gandhi ceased to be Director.
35 earlier events are in the company report.
News
Frequently asked questions
Vaishali Pharma is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 25 April 2008 (18+ years old) and is registered under CIN L52310MH2008PLC181632. Listed on NSE: VAISHALI.
Vaishali Pharma reported revenue of ₹108.77 Cr for FY 2025-26 (up 9.8% YoY) based on standalone financials.
Vaishali Pharma has 5 current directors:
- Atul Arvind Vasani - Managing Director
- Jagruti Atul Vasani - Whole-Time Director
- Dewansh Ajay Vasani - Director
- Manish Bhagwandas Ved - Director
- Pratik Vikram Jakhelia - Director
The latest financial statements of Vaishali Pharma on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 22 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Vaishali Pharma is 27AACCV7258G1Z1, registered in Maharashtra. The company has 4 GST registrations in all, of which 1 is active and 3 are cancelled or inactive.
The CIN (Corporate Identification Number) of Vaishali Pharma is L52310MH2008PLC181632. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Vaishali Pharma is a listed company as per MCA records. Its shares are listed on NSE (symbol: VAISHALI).
Vaishali Pharma has 19 court cases on record: 5 filed by the company and 14 filed against it. 6 are pending. Most are in the district courts.
Vaishali Pharma was incorporated on 25 April 2008, making it 18+ years old. It is registered with the Registrar of Companies, Mumbai.
Vaishali Pharma has 135 deals on record (134 market trades, 1 ipo); the latest was in October 2025.
Ratnesh Raghunath Singh ceased to be CFO on 28 Feb 2025. Ashvin Jamnadas Ganatra ceased to be Director on 24 Jan 2025. Prataprai Panachand Gandhi ceased to be Director on 12 Jul 2021. Vaishali Pharma has 19 board changes on record in total.